OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.63 Million CAD | 53.75% |
| 2022 | 2.36 Million CAD | -51.63% |
| 2021 | 4.88 Million CAD | -95.29% |
| 2020 | 103.67 Million CAD | 125.04% |
| 2019 | 46.06 Million CAD | -53.35% |
| 2018 | 98.74 Million CAD | 3056.25% |
| 2017 | 3.12 Million CAD | -56.31% |
| 2016 | 7.16 Million CAD | 56.55% |
| 2015 | 4.57 Million CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 65 Thousand CAD | -17.72% |
| 2024 Q3 | 39 Thousand CAD | -25.0% |
| 2024 Q2 | 52 Thousand CAD | -20.0% |
| 2023 Q3 | 100 Thousand CAD | -15.25% |
| 2023 Q1 | 137 Thousand CAD | -94.2% |
| 2023 Q2 | 118 Thousand CAD | -13.87% |
| 2023 FY | 79 Thousand CAD | -96.65% |
| 2023 Q4 | 79 Thousand CAD | -21.0% |
| 2022 Q1 | 3.07 Million CAD | -37.02% |
| 2022 Q2 | 2.87 Million CAD | -6.57% |
| 2022 Q3 | 2.61 Million CAD | -8.88% |
| 2022 FY | 2.36 Million CAD | -51.63% |
| 2022 Q4 | 2.36 Million CAD | -9.78% |
| 2021 Q2 | 52.75 Million CAD | -8.88% |
| 2021 Q3 | 5.14 Million CAD | -90.24% |
| 2021 Q4 | 4.88 Million CAD | -5.19% |
| 2021 FY | 4.88 Million CAD | -95.29% |
| 2021 Q1 | 57.9 Million CAD | -44.15% |
| 2020 Q3 | 81.64 Million CAD | 3840.15% |
| 2020 Q2 | 2.07 Million CAD | -97.42% |
| 2020 Q1 | 80.27 Million CAD | 74.27% |
| 2020 Q4 | 103.67 Million CAD | 26.99% |
| 2020 FY | 103.67 Million CAD | 125.04% |
| 2019 Q4 | 46.06 Million CAD | -2.39% |
| 2019 FY | 46.06 Million CAD | -53.35% |
| 2019 Q3 | 47.19 Million CAD | 329.21% |
| 2019 Q2 | 10.99 Million CAD | -88.81% |
| 2019 Q1 | 98.29 Million CAD | -0.45% |
| 2018 Q4 | 98.74 Million CAD | 0.48% |
| 2018 FY | 98.74 Million CAD | 3056.25% |
| 2018 Q1 | 3.01 Million CAD | -3.52% |
| 2018 Q2 | 95.88 Million CAD | 3076.83% |
| 2018 Q3 | 98.26 Million CAD | 2.48% |
| 2017 Q1 | 3.39 Million CAD | -52.55% |
| 2017 Q2 | 3.28 Million CAD | -3.37% |
| 2017 FY | 3.12 Million CAD | -56.31% |
| 2017 Q3 | 3.19 Million CAD | -2.54% |
| 2017 Q4 | 3.12 Million CAD | -2.23% |
| 2016 FY | 7.16 Million CAD | 56.55% |
| 2016 Q3 | 7.24 Million CAD | -1.14% |
| 2016 Q2 | 7.32 Million CAD | 3.08% |
| 2016 Q1 | 7.1 Million CAD | 55.41% |
| 2016 Q4 | 7.16 Million CAD | -1.15% |
| 2015 Q1 | 2.28 Million CAD | 0.0% |
| 2015 FY | 4.57 Million CAD | 0.0% |
| 2015 Q4 | 4.57 Million CAD | 107.02% |
| 2015 Q3 | 2.2 Million CAD | -1.98% |
| 2015 Q2 | 2.25 Million CAD | -1.41% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 51.26 Million USD | 92.919% |
| Harrow Health, Inc. | 183.17 Million USD | 98.018% |
| Dynavax Technologies Corporation | 252.41 Million USD | 98.562% |
| Biofrontera Inc. | 804 Thousand USD | -351.493% |
| Cronos Group Inc. | 1.55 Million USD | -132.842% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -4072.414% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.272% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 89.383% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -697.802% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 71.605% |
| Radius Health, Inc. | 339.66 Million USD | 98.931% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| DURECT Corporation | 2.7 Million USD | -34.345% |
| ProPhase Labs, Inc. | 10.25 Million USD | 64.613% |
| Safety Shot Inc | 304.9 Thousand USD | -1090.527% |
| Phibro Animal Health Corporation | 458.28 Million USD | 99.208% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -2999.147% |
| Alvotech | 1.02 Billion USD | 99.647% |
| Assertio Holdings, Inc. | 38.51 Million USD | 90.575% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 89.065% |
| Rockwell Medical, Inc. | 8.29 Million USD | 56.228% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -573.426% |
| Procaps Group S.A. | 28.41 Million USD | 87.223% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 72.76% |
| SCYNEXIS, Inc. | 12.15 Million USD | 70.146% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 66.627% |
| Viatris Inc. | 16.18 Billion USD | 99.978% |
| OptiNose, Inc. | 611 Thousand USD | -494.108% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -980.386% |
| Tilray Brands, Inc. | 287.93 Million USD | 98.739% |
| PetIQ, Inc. | 437.82 Million USD | 99.171% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -573.426% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 98.595% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 64.48 Million USD | 94.371% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.259% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -2587.117% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 94.024% |
| Journey Medical Corporation | 14.62 Million USD | 75.174% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | 47.064% |
| Alpha Teknova, Inc. | 13.25 Million USD | 72.606% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -404.167% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 96.988% |
| PainReform Ltd. | 30 Thousand USD | -12000.0% |
| Cosmos Health Inc. | 3.03 Million USD | -19.591% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 88.919% |
| TherapeuticsMD, Inc. | 6.53 Million USD | 44.427% |
| Embecta Corp. | 1.62 Billion USD | 99.777% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 99.293% |
| Incannex Healthcare Limited | 210 Thousand USD | -1628.571% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -16044.814% |
| Shineco, Inc. | 10.01 Million USD | 63.763% |
| Procaps Group, S.A. | 28.41 Million USD | 87.223% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 98.828% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 96.014% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 99.411% |
| Alvotech | 1.02 Billion USD | 99.647% |
| Hempacco Co., Inc. | 5.93 Million USD | 38.796% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 93.543% |
| Bright Green Corporation | 201.78 Thousand USD | -1698.962% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.276% |
| Kamada Ltd. | 7.43 Million USD | 51.197% |
| Indivior PLC | 235.66 Million USD | 98.46% |
| Evoke Pharma, Inc. | 5 Million USD | 27.4% |
| Flora Growth Corp. | 942 Thousand USD | -285.35% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -16044.814% |
| Evolus, Inc. | 120.35 Million USD | 96.984% |
| HUTCHMED (China) Limited | 48.18 Million USD | 92.467% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.384% |
| Akanda Corp. | 2.49 Million USD | -45.365% |